PREVENT Equations Reclassify Half of U.S. Adults to Lower ASCVD Risk

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, Aug. 2, 2024 -- Use of the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations instead of the 2013 recommended pooled cohort equations for estimating the 10-year risk for atherosclerotic cardiovascular disease could result in a considerable decrease in the number of adults receiving or recommended for preventive treatment with statin or antihypertensive therapy, according to a study published online July 29 in the Journal of the American Medical Association.

James A. Diao, M.D., from Harvard Medical School in Boston, and colleagues estimated changes in risk categorization, treatment eligibility, or clinical outcomes when applying PREVENT equations to existing American College of Cardiology (ACC) and American Heart Association (AHA) guidelines. Data were included for a sample of 7,765 U.S. adults aged 30 to 79 years who participated in the National Health and Nutrition Examination Surveys from 2011 to March 2020.

The researchers estimated that using PREVENT equations would reclassify about half (53 percent) of U.S. adults to lower ACC and AHA risk categories and very few (0.41 percent) to higher risk categories. There would be an estimated decrease in the number of U.S. adults receiving or recommended for preventive treatment of 14.3 million for statin therapy and 2.62 million for antihypertensive therapy. These decreases could result in 107,000 additional occurrences of myocardial infarction or stroke over 10 years. The changes in eligibility would affect twice as many men as women and a greater proportion of Black than White adults.

"The magnitude of these projected changes warrants careful reconsideration of current treatment thresholds using decision-analytic or cost-effectiveness frameworks," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-03 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords